TL;DR: When contaminated cannabis product reaches retail, the enforcement machinery that follows looks nothing like a food or drug recall. There is no federal FDA recall authority for cannabis. Each state runs its own recall framework with its own triggers, timelines, and liability consequences — and processors bear substantially more direct exposure than the retail or distribution tiers above them in the chain. The New York 54-lot recall triggered by the Keystone Lab scandal and Michigan's permanent ban of Viridis Laboratories are the two most instructive recent enforcement events — not because they are exceptional, but because they document, in public regulatory records, exactly what happens when the contamination control system fails. The processor who understands that trajectory in advance, and builds the documentation architecture that interrupts it, is in a fundamentally different legal and regulatory position than the one who doesn't.
Key Takeaways
- Cannabis recalls are state-administered, not federally coordinated — each state has different recall triggers, mandatory disclosure timelines, and documentation requirements, and there is no FDA enforcement umbrella to provide consistency
- The New York Keystone Lab recall (March 2026) covered 54+ lots across multiple operators for false Aspergillus and heavy metal results — processors whose product was tested by Keystone faced recalls regardless of their own quality practices
- Michigan's Viridis Laboratories permanent ban (August 2025) documented a "sustained, deliberate pattern" of mold and potency fraud that drove compliant testing competitors out of business — operators relying on Viridis COAs had no independent basis to know their product was non-compliant
- Processor liability in a contamination recall can be civil (product liability, contract claims from retail partners), administrative (license suspension, mandatory remediation orders, destruction costs), and in egregious cases criminal
- The documentation gap that creates maximum liability exposure is not failing a test — it is having no process records demonstrating that contamination control was ever attempted before the product entered the distribution chain
- In-process contamination control creates a batch-level evidentiary record that is the single most effective liability mitigation tool available to processors — more durable than any COA from any lab
How Cannabis Recalls Actually Work
The starting assumption many cannabis operators carry — that recalls are administered the way food or pharmaceutical recalls are, with an FDA enforcement structure, mandatory federal reporting, and a coordinated national response system — is incorrect for cannabis.
Cannabis remains a Schedule I controlled substance under federal law, and the FDA has no authority to mandate cannabis product recalls or coordinate multi-state enforcement actions. Every recall is state-administered, initiated by the state regulatory agency, and limited in scope to the licensed distribution chain within that state. A contamination event in New York does not trigger an automatic recall inquiry in California, even if the same product was shipped across state lines through licensed distribution.
What state-level recalls do have is speed and consequence. When a state cannabis regulatory agency identifies a potential contamination issue — through a testing laboratory report, a consumer complaint, a retail partner notification, or its own enforcement inspection — the recall workflow moves quickly.
The typical state recall sequence:
1. Voluntary recall request. Most state agencies begin with a voluntary recall request to the licensee — a directive to pull identified lots from retail, notify distribution partners, and begin product recovery. "Voluntary" is a term of art here: compliance is effectively mandatory, and refusal to comply with a voluntary recall request typically triggers a mandatory order with additional penalties.
2. Mandatory hold and notification. The regulatory agency issues a mandatory hold on all affected lots still in the licensed distribution chain, simultaneously notifying retail licensees that the product must be removed from sale. The processor is required to provide documentation identifying all lots affected, all distribution recipients, and the testing history of each lot.
3. Regulatory investigation. Once the recall mechanics are underway, the agency opens an investigation into the source of the contamination — which may include an inspection of the processor's facility, a review of the processor's batch records and COA history, and in cases involving testing irregularities, an inquiry into the laboratory relationship.
4. Disposition. Recalled product must either be retested and cleared, remediated and retested, or destroyed. In contamination recalls (as opposed to labeling recalls), remediation pathways are often not available — mycotoxin and pathogen contamination typically requires destruction. Destruction costs accrue to the processor.
5. Enforcement follow-on. After the recall mechanics are resolved, the regulatory agency determines whether enforcement action against the processor is warranted. This is where the documentation the processor maintained — or failed to maintain — becomes determinative.
What the Keystone and Viridis Cases Document
The two most instructive recent enforcement events are worth examining in detail, because they illustrate two different liability pathways — one where the processor is a passive victim of a corrupt laboratory, and one where the laboratory fraud is the mechanism through which processors escaped accountability for contamination that was likely real.
The New York Keystone Lab Recall (March 2026)
New York's Office of Cannabis Management (OCM) issued a voluntary recall directive in March 2026 covering more than 54 lots of cannabis products that had been tested by Keystone Testing Laboratory. The recall was triggered by OCM's determination that Keystone had issued false certificates of analysis — specifically, fabricating passing results for Aspergillus species testing and heavy metal panels where the actual product may have failed.
A concurrent investigation resulted in Lexachrom Analytical Laboratory, which operated Keystone, facing fines of up to $2 million and the permanent revocation of its testing laboratory license.
For processors whose product was caught in this recall, the liability exposure had nothing to do with their own quality practices. They had followed the compliance pathway — tested product, received passing COAs, and placed product in the distribution chain — and the COAs were fabricated. The recall was not their fault in any causal sense.
And yet: they faced mandatory product removal, destruction costs for non-clearable lots, revenue disruption, retail partner relationship damage, and in some cases OCM inquiries into whether the laboratory relationship itself should have raised red flags. As the cannabis lab testing fraud analysis documented, the operators most exposed to a corrupt laboratory recall are those with no independent basis — no in-house process records, no contamination history, no pre-testing contamination control documentation — to demonstrate that their product was likely compliant regardless of the COA.
The Michigan Viridis Permanent Ban (August 2025)
The Michigan Cannabis Regulatory Agency's August 2025 permanent ban of Viridis Laboratories used the phrase "sustained, deliberate pattern" of mold and potency fraud — language that appeared in the agency's formal order and has been cited in subsequent Michigan enforcement guidance as the standard for conduct warranting permanent license revocation rather than suspension.
The Viridis case documents the other side of laboratory fraud liability. Where Keystone-affected processors were victims of fabricated passing results, Viridis-affected operators are documented — in public regulatory records — as having placed product in the Michigan retail market based on COAs that the testing laboratory manufactured rather than earned. Some of that product was, in all likelihood, contaminated.
For processors who relied on Viridis COAs and whose products are now associated with a permanently banned laboratory in public records, the liability landscape is materially different from the Keystone situation. Civil claims from retail partners who relied on those COAs to accept and sell the product. Potential consumer claims if contaminated product caused illness. Regulatory inquiries into whether the operator's quality system should have independently detected the contamination that Viridis was falsifying. And the reputational consequence of having a laboratory relationship that a state regulatory agency described as operating through deliberate fraud.
Both cases lead to the same operational conclusion: a passing COA is necessary for compliance but insufficient for liability protection. The protection comes from what exists in the processor's records before the COA was ever requested.
Liability Exposure: Civil, Administrative, and Criminal
Cannabis processor liability in a contamination recall event runs across three distinct channels, each with different exposure profiles and different documentation defenses.
Civil Liability
When contaminated cannabis product reaches retail, the processor faces potential civil claims from retail licensees who purchased in good faith, distribution partners who transferred product that turns out non-compliant, and in cases of consumer illness, product liability claims from end consumers.
The core product liability principle is consistent across jurisdictions: a processor who manufactures and places into commerce a product that causes harm bears liability for that harm. Cannabis's regulatory complexity does not eliminate this exposure — in some states, the existence of a licensed compliance framework the processor failed to satisfy actually strengthens the liability case by establishing a standard of care.
Administrative Liability
Administrative liability — license suspension, mandatory remediation orders, fines, forced destruction costs — is the most immediate consequence of a contamination recall. Regulatory agencies investigating a recall look for evidence that the processor operated a quality system: batch records, documented testing history, contamination control SOPs. The absence of this documentation actively supports an inference of negligent quality practices that justifies more aggressive enforcement.
As New York's March 2026 GMP enforcement guidance has made explicit, the expectation that licensed processors operate documented quality systems is no longer aspirational — it is an enforcement standard. Processors who cannot produce batch records or SOPs during a recall investigation are not simply disorganized. They are operating outside the documented expectations of their licensing framework.
Criminal Liability
Criminal liability in cannabis contamination cases is rare but not theoretical. It requires a showing of knowledge or reckless disregard — that the processor knew or should have known the product was non-compliant and placed it in commerce anyway. The Viridis permanent ban language suggests the laboratory's principals may face criminal referral precisely because "sustained, deliberate pattern" implies knowledge and intent.
For processors, the criminal exposure scenario involves a documented pattern of prior contamination failures — prior failing COAs, prior recalls, prior remediation events — followed by continued product releases without quality system changes.
The Documentation That Limits Liability
The single most consequential quality of a processor's documentation in a recall investigation is this: does it establish that contamination control was attempted and documented before the product entered the distribution chain?
A processor who can present, for every lot in a recall investigation:
- A batch-level decontamination process record showing that validated contamination control was applied before testing
- A COA from a licensed, independent laboratory showing the analyte results at the time of testing
- An SOP that governed the decontamination process and was in effect at the time of the event
- A deviation log showing that any out-of-specification conditions during the decontamination cycle were identified and resolved
...is in a qualitatively different legal and regulatory position than a processor whose only documentation is the COA itself.
The COA alone establishes that the product passed testing at a specific moment in time at a specific laboratory. It says nothing about what the processor did to ensure the product was safe before testing. When the laboratory is subsequently found to be fraudulent — as in the Keystone and Viridis cases — the COA's evidentiary value collapses entirely. The processor's process records survive that collapse.
This is the operational argument for in-process contamination control as a liability management tool, not just a quality tool. VHP decontamination applied before a lot enters the testing pipeline produces a batch-level process record — cycle parameters, exposure duration, environmental monitoring results, validated log-reduction claim — that exists independently of any laboratory relationship. That record doesn't change when a laboratory loses its license. It doesn't become worthless when a COA is found to be fabricated. It is the processor's own documented evidence that contamination control happened, under defined conditions, before the product was tested.
As detailed in What 'cGMP Ready' Actually Means for Cannabis Processors in 2026, this documentation architecture is also what GMP frameworks require and what the coming FDA oversight wave will expect. Building it now — before a recall investigation — is the time to do it.
What the Enforcement Trajectory Tells Processors
The Viridis and Keystone cases are not outliers. They are the leading edge of an enforcement trajectory that cannabis lab testing fraud analysis has documented accelerating since 2024: more states with active testing programs, more regulatory agencies with dedicated enforcement staff reviewing COA data for anomalies, and more laboratory fraud cases producing public enforcement actions that drag processors into recall and investigation proceedings.
The Massachusetts MCR Labs case — where MCR Labs sued eight competitor labs while Assured Testing Labs was suspended for failing to report yeast and mold in more than 7,000 samples — adds another dimension: even in markets without a high-profile fraud case, the structural incentives for laboratory COA manipulation are documented and known to regulators. Every state that has looked closely at its testing data has found anomalies.
For processors, the policy implication is clear: the compliance question is not "did my product pass testing?" It is "if my laboratory relationship became the subject of a regulatory investigation tomorrow, what would my own records show?" The answer to that question — and the documentation architecture that makes it a strong answer — is what separates operators who survive the coming enforcement cycle from those who don't.
For the full context on cannabis laboratory fraud and COA reliability, see The Cannabis Lab Testing Fraud Crisis: Why You Can't Rely on a Passing COA. For the cGMP documentation architecture that recall investigations assume processors have built, see What 'cGMP Ready' Actually Means for Cannabis Processors in 2026. For the FDA oversight trajectory that makes this documentation architecture increasingly mandatory, see Schedule III Rescheduling and the Coming FDA Oversight Wave.